Disease Landscape and Forecast Insights

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs…

MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin; it typically develops in early childhood and can persist into…

The systemic sclerosis (SSc) pipeline is replete with therapies targeting pathways underlying autoimmunity, inflammation, and fibrosis, particularly in the early phases of development. Currently,…

Research on the human microbiome is expanding beyond C. difficile, with microbiome-based therapies reaching the clinical trial phase of development for additional disease areas. Investments in this…

The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of Sun Ophthalmics’ Cequa at a competitive…

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key major depressive disorder patient populations covering 171 countries and…

DRG Epidemiology’s coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…

DRG Epidemiology’s coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…

DRG Epidemiology’s coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…

DRG Epidemiology’s coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…

DRG Epidemiology’s coverage of minor depression comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of minor depression for each…